[Respiratory effects of chronic therapy with latanoprost in patients with chronic obstructive pulmonary disease (COPD)].
To study the respiratory effects of chronic therapy with latanoprost in Chronic Obstructive Pulmonary Disease (COPD) patients. We prospectively performed a spirometry in 19 COPD patients treated with latanoprost for more than 3 months, and the same masked-examiner repeated the test, under the same conditions, one week after latanoprost wash-out. We found that latanoprost withdrawal increased forced espiratory volume (FEV1) (litre) from 1.5 S.D. 0.5 to 1.6 S.D. 0.5 and FEV1/FVC (forced vital capacity) index from 64.4 S.D. 8.6% to 66.5 S.D. 7.7% (both comparisons p=0.02, Wilcoxon signed-rank test). Chronic therapy with latanoprost seems to induce a mild, though statistically significant, bronchoconstriction in COPD patients.